Scovella (velagliflozin): What Equine Vets Need to Know

The first licensed SGLT2 inhibitor for horses – what the trials show, what they don't, and what to monitor.

A New Option for Insulin-Dysregulated Horses

Until now, vets using SGLT2 inhibitors in horses have relied on human medicines or compounded products under the cascade. Scovella (velagliflozin) is the first gliflozin licensed for horses and ponies, for hyperinsulinaemia that has not responded to changes in husbandry and exercise.

In this edition of Spotlight on Medicines, Ask Andrea introduces our new CPD module on Scovella.

What Our Scovella Review Covers

• Trial evidence: how well velagliflozin lowers insulin, how long the effect lasts, and what is (and isn't) known about laminitis.

• Cascade prescribing: the VMD's advice on new cases and on horses already treated with an unlicensed SGLT2 inhibitor.

• Safety: raised triglycerides, weight loss, and increased urination and drinking.

• Practical tools: baseline tests and monitoring, duration of treatment, cost, and what to say to owners.

• Licensing: what the "limited marketing authorisation" on the pack actually means.

Access the Full Subscriber Review

Subscribers can log in to read or listen to the full module, take the quiz and get a CPD certificate.